...
机译:Mapatumumab的II期试验,一种肿瘤坏死因子相关凋亡诱导配体受体1(TRAI-R1)的全人激动剂单克隆抗体,与PACLITAXEL和CAROBOLATIN联合治疗未小的非小细胞肺癌患者
Department of Oncology Asklepios-Fachkliniken München-Gauting Munich Germany;
Alabama Oncology Birmingham AL United States;
Tennessee Oncology Sarah Cannon Research Institute Nashville TN United States;
Department of Medical Oncology Institute of Oncology Prof. Dr. Alexandru Trestioreanu Bucharest;
Department of Thoracic Oncology Hospital Grosshansdorf Grosshansdorf Germany;
Department of Radiotherapy I-Medical Oncology Prof Dr Ion Chircuta Institute of Oncology Cluj;
Preclinical Research Rockville MD United States;
Department of Biostatistics Rockville MD United States;
Clinical Research Human Genome Sciences Rockville MD United States;
Division of Medical Oncology Department of Medicine University of Colorado Aurora CO United;
Carboplatin/paclitaxel combination; Death receptors; Targeted biological agent;
机译:Mapatumumab(一种针对肿瘤坏死因子相关的凋亡诱导配体受体1(TRAIL-R1)的全人类激动剂单克隆抗体)与紫杉醇和卡铂联合用于晚期非小细胞肺癌患者的II期临床试验
机译:208 HGS-ETR1,一种针对晚期实体癌患者的肿瘤坏死因子相关的凋亡诱导配体死亡受体1(TRAIL-R1)的全人类单克隆抗体:I期试验的结果
机译:208 HGS-ETR1,一种针对晚期实体癌患者的肿瘤坏死因子相关的凋亡诱导配体死亡受体1(TRAIL-R1)的全人类单克隆抗体:I期试验的结果
机译:I / II期临床试验关于每周紫杉醇(WPTX)和WPTX含有晚期和转移性胃癌组合方案的临床试验 - 分泌组研究
机译:在人类破骨细胞模型中调节肿瘤坏死因子相关的凋亡诱导配体(TRAIL)受体。
机译:mapatumumab的II期临床试验这是一种完全的人类激动性单克隆抗体可靶向和激活肿瘤坏死因子凋亡诱导配体受体1(TRAIL-R1)用于难治性大肠癌患者
机译:mapatumumab的II期临床试验,这是一种完全的人类激动性单克隆抗体,可靶向和激活肿瘤坏死因子凋亡诱导配体受体1(TRAIL-R1),用于难治性大肠癌患者